Genomic solutions for oncology clinical trials
CLIA/CAP-certified sequencing & bioinformatics for pharma, biotech and CRO partners
IntegraGen is a reference genomics partner for oncology clinical trials, with a CLIA/CAP-certified laboratory, advanced bioinformatics and logistics adapted to clinical studies.
We work with academic sponsors, biotechs and CROs on clinical studies, at every stage of the process, with reliability, flexibility and regulatory compliance.
These certifications ensure that IntegraGen meets the highest standards of quality and accuracy in clinical laboratory testing, making the company a trusted partner for companies involved in drug development and clinical trials.
Complete workflow
- Sample logistics
- Organization of pick-ups from investigating centers and logistical traceability.
- Liaison with investigating centers
- Operational support with eTRFs, sample management guides and technical assistance.
- NGS analysis
- Whole Exome Sequencing (WES).
- Whole Genome Sequencing (WGS).
- RNA-seq.
- Minimal Residual Disease (MRD) .
- All analyses are carried out in our CLIA/CAP-certified laboratory in Évry (France).
- Bioinformatics & Rendering
- Secure rendering.
- Turnaround times (TAT) mapped out and shared with sponsors/CROs.
Our added value
IntegraGen offers specialized sequencing services and clinical experience recognized by leading academic centers:
- Excellence in sequencing since 2009
- Exclusive rights to sequence biological samples.
- Simplified processes / Optimized European logistics
- Reduced risk in sample management, no regulatory constraints in France.
- Network of trust & recommendations
- Leading clinical centers (Gustave Roussy, Institut Pasteur, Bergonié...) recommend IntegraGen.
- CLIA/CAP-certified laboratory
- Validated quality system and access to sponsor audits.
They put their trust in us
IntegraGen is a partner in clinical projects run by leading academic centers and hospitals.
IntegraGen contributes to the UMBRELLA study conducted by Gustave Roussy, a multicenter Phase III trial in which MRD (circulating tumor DNA) status guides the follow-up of non-metastatic cancer patients. A study sponsored by Gustave Roussy and incorporating Veracyte's MRD technology.
Our CLIA/CAP-certified platform supports :
- Kit production and multi-center logistics (France)
- Extraction and processing of tumor DNA (FFPE), germline DNA (PBMC) and plasma DNA (cfDNA)
- WGS sequencing on NovaSeq X+
- Secure data transfer and automated generation of clinical reports via our digital infrastructure
With over 700 patients expected, UMBRELLA is a concrete example of how IntegraGen delivers precision, reliability and speed in complex oncology trials.
